Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07116967) titled 'Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)' on Aug. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Bristol-Myers Squibb
Condition:
Plaque Psoriasis
Intervention:
Drug: Deucravacitinib
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 30, 2025
Target Sample Size: 3040
Countries of Recruitment:
United States
Argentina
Australia
Belgium
Brazil
Canada
Chile
China
Czechia
Denmark
F...